文献速递糖尿病

开发与验证最优表型映射方法以评估2型糖尿病患者长期动脉粥样硬化性心血管疾病风险

Development and validation of optimal phenomapping methods to estimate long-term atherosclerotic cardiovascular disease risk in patients with type 2 diabetes.
PubMed 文献 · Diabetologia · 2021-03-13

本研究基于ACCORD试验中6466例无基线CVD的2型糖尿病患者,比较四种表型映射策略,发现有限混合模型(FMM)表现最佳,可识别出三个特征不同的表型组,且表型组与强化降糖、联合调脂等治疗对主要复合结局风险存在显著交互作用。外部验证在Look AHEAD和BARI 2D试验中独立进行。

要点

  • FMM三表型组聚类在推导和验证队列中均表现最佳。
  • 表型组1合并症和糖尿病并发症负担最高,表型组3最低。
  • 表型组3低危患者从强化降糖、联合调脂等干预中获益更明显。

核心结论

  • 采用FMM聚类是识别2型糖尿病可重复亚组的最佳表型映射策略,这些亚组具有不同临床特征、CVD风险和治疗反应。

研究设计与样本

  • 研究纳入ACCORD试验中6466例无基线CVD的2型糖尿病患者,比较高斯混合模型、潜在类别分析、有限混合模型(FMM)和主成分分析四种聚类策略。
  • 外部验证独立在Look AHEAD试验(n=4211)和BARI 2D试验(n=1495)中进行。

主要发现

  • 中位随访9.1年期间,789例(12.2%)发生主要结局事件。
  • FMM三表型组聚类在推导和验证队列中依贝叶斯信息准则、Dunn指数和模型区分度改善均表现最佳。
  • 表型组1(n=663,10.3%)合并症和糖尿病并发症负担最高,表型组2(n=2388,36.9%)合并症中等且糖尿病并发症最低,表型组3(n=3415,52.8%)合并症最少且糖尿病并发症中等。
  • 表型组与强化降糖(交互p=0.042)、联合调脂(交互p<0.001)在ACCORD中,与强化生活方式干预(交互p=0.002)在Look AHEAD中,与早期冠状动脉血运重建(交互p=0.003)在BARI 2D中对主要复合结局风险存在显著交互作用。
  • 表型组3低危参与者中观察到这些干预对主要复合结局风险有利降低,其他表型组未见。

关键数值与推荐

  • FMM三表型组聚类为最佳策略,依据贝叶斯信息准则、Dunn指数和模型区分度改善。
  • 表型组与强化降糖交互p=0.042,与联合调脂交互p<0.001(ACCORD),与强化生活方式干预交互p=0.002(Look AHEAD),与早期冠状动脉血运重建交互p=0.003(BARI 2D)。

临床怎么用

  • FMM表型映射可用于对2型糖尿病患者进行风险分层,识别可能从特定强化治疗中获益更多的低危亚组。

局限性

  • 表型组1参与者随访中严重/症状性低血糖事件和药物不依从更常见(ACCORD和Look AHEAD队列)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Type 2 diabetes is a heterogeneous disease process with variable trajectories of CVD risk. We aimed to evaluate four phenomapping strategies and their ability to stratify CVD risk in individuals with type 2 diabetes and to identify subgroups who may benefit from specific therapies. METHODS: Participants with type 2 diabetes and free of baseline CVD in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial were included in this study (N = 6466). Clustering using Gaussian mixture models, latent class analysis, finite mixture models (FMMs) and principal component analysis was compared. Clustering variables included demographics, medical and social history, laboratory values and diabetes complications. The interaction between the phenogroup and intensive glycaemic, combination lipid and intensive BP therapy for the risk of the primary outcome (composite of fatal myocardial infarction, non-fatal myocardial infarction or unstable angina) was evaluated using adjusted Cox models. The phenomapping strategies were independently assessed in an external validation cohort (Look Action for Health in Diabetes [Look AHEAD] trial: n = 4211; and Bypass Angioplasty Revascularisation Investigation 2 Diabetes [BARI 2D] trial: n = 1495). RESULTS: Over 9.1 years of follow-up, 789 (12.2%) participants had a primary outcome event. FMM phenomapping with three phenogroups was the best-performing clustering strategy in both the derivation and validation cohorts as determined by Bayesian information criterion, Dunn index and improvement in model discrimination. Phenogroup 1 (n = 663, 10.3%) had the highest burden of comorbidities and diabetes complications, phenogroup 2 (n = 2388, 36.9%) had an intermediate comorbidity burden and lowest diabetes complications, and phenogroup 3 (n = 3415, 52.8%) had the fewest comorbidities and intermediate burden of diabetes complications. Significant interactions were observed between phenogroups and treatment interventions including intensive glycaemic control (p-interaction = 0.042) and combination lipid therapy (p-interaction < 0.001) in the ACCORD, intensive lifestyle intervention (p-interaction = 0.002) in the Look AHEAD and early coronary revascularisation (p-interaction = 0.003) in the BARI 2D trial cohorts for the risk of the primary composite outcome. Favourable reduction in the risk of the primary composite outcome with these interventions was noted in low-risk participants of phenogroup 3 but not in other phenogroups. Compared with phenogroup 3, phenogroup 1 participants were more likely to have severe/symptomatic hypoglycaemic events and medication non-adherence on follow-up in the ACCORD and Look AHEAD trial cohorts. CONCLUSIONS/INTERPRETATION: Clustering using FMMs was the optimal phenomapping strategy to identify replicable subgroups of patients with type 2 diabetes with distinct clinical characteristics, CVD risk and response to therapies.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Segar MW, Patel KV, Vaduganathan M, et al. Development and validation of optimal phenomapping methods to estimate long-term atherosclerotic cardiovascular disease risk in patients with type 2 diabetes. Diabetologia. 2021. PMID: 33715025. doi:10.1007/s00125-021-05426-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。